Rapid-Onset Migraine Prevention with Eptinezumab
A detailed presentation on the effectiveness of Eptinezumab in providing rapid and sustained preventative relief for migraine patients, supported by an educational grant from Lilly. Key messages and background information from the American Headache Society's virtual annual scientific meeting are highlighted, emphasizing the unmet need for a preventative treatment with quick clinical benefits.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
SLIDE KIT THIS ACTIVITY IS SUPPORTED BY AN EDUCATIONAL GRANT FROM LILLY For further information concerning Lilly grant funding visit www.lillygrantoffice.com www.lillygrantoffice.com
SLIDE KIT Eptinezumab EptinezumabDemonstrated Migraine Preventive Efficacy on Day 1 Demonstrated Migraine Preventive Efficacy on Day 1 After After Dosing: Closed Testing Analysis from PROMISE Dosing: Closed Testing Analysis from PROMISE- -1 and PROMISE PROMISE- -2 2 1 and Presented by David W. Dodick, MD Professor, Mayo Clinic Scottsdale, Arizona Developed by Infomedica Medical Education& Information AHS Virtual Annual Scientific Meeting content is made available to an international audience through a licensing agreement between Infomedica and the American Headache Society. Infomedica is an independent medical education provider that delivers medical information to healthcare professionals through conference coverage and online educational programs and activities.
A M E R I C A N H E A D A C H E S O C I E T Y V I R T U A L A N N U A L S C I E N T I F I C M E E T I N G O F F I C I A L H I G H L I G H T S Key messages Key messages Patients seek preventative treatments that deliver a rapid onset of clinical benefit. Eptinezumab provides rapid and sustained preventative migraine relief for patients who experience both episodic and chronic migraine. Eptinezumab prevents the occurrence of migraine from day one following intravenous administration and is sustained for up to 12 weeks in the majority of patients. DEVELOPED BY
A M E R I C A N H E A D A C H E S O C I E T Y V I R T U A L A N N U A L S C I E N T I F I C M E E T I N G O F F I C I A L H I G H L I G H T S Background Background What do we already know about this topic? A preventative treatment that delivers rapid clinical benefit remains an unmet need in migraine. Eptinezumab, a humanized anti-calcitonin gene-related peptide monoclonal antibody (anti-CRGP mAb) demonstrated efficacy and a rapid onset of action in two Phase III, double-blind, randomized, placebo-controlled trials (PROMISE-1 and PROMISE-2) that evaluated eptinezumab for migraine prevention.1,2 A post-hoc analysis was carried out to confirm whether the percentage of patients with a migraine on Day 1 after eptinezumab administration measured onset of full preventive effect. DEVELOPED BY
A M E R I C A N H E A D A C H E S O C I E T Y V I R T U A L A N N U A L S C I E N T I F I C M E E T I N G O F F I C I A L H I G H L I G H T S Background Background How was this study conducted? PROMISE-1 and PROMISE-2 were Phase III, double-blind, randomized, placebo-controlled clinical trials evaluating eptinezumab 100 mg, 300 mg, or placebo for migraine prevention in patients with episodic (n=888) and chronic (n=1072) patients.1,2 A post-hoc closed testing procedure analyzing the proportion of patients experiencing a migraine was used on progressively smaller time intervals from Weeks 1 to 12, Days 1 to 84. For each interval that demonstrated statistical significance (p 0.05), the interval was reduced by 1 day and treatment effect was tested again. The procedure was stopped at the time point where statistical significance was not achieved, and the onset of preventive efficacy was declared as the end day of the prior interval. DEVELOPED BY
A M E R I C A N H E A D A C H E S O C I E T Y V I R T U A L A N N U A L S C I E N T I F I C M E E T I N G O F F I C I A L H I G H L I G H T S Findings Findings What does this study add? In both studies, patients on eptinezumab 100 mg and 300 mg achieved a significant mean reduction in monthly migraine days (p< 0.05) from Day 84 to Day 1 across all tests, indicating that eptinezumab was effective from Day 1 after dosing. The response was sustained for 12 weeks following the initial dose. DEVELOPED BY
A M E R I C A N H E A D A C H E S O C I E T Y V I R T U A L A N N U A L S C I E N T I F I C M E E T I N G O F F I C I A L H I G H L I G H T S Perspectives Perspectives How does this study impact clinical practice? Eptinezumab provides rapid and sustained migraine relief for patients who experience both episodic and chronic migraine. Eptinezumab prevents the occurrence of migraine from day one following intravenous administration and is sustained for up to 12 weeks in the majority of patients. DEVELOPED BY
A M E R I C A N H E A D A C H E S O C I E T Y V I R T U A L A N N U A L S C I E N T I F I C M E E T I N G O F F I C I A L H I G H L I G H T S References References 1. Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 2020;40:241-254. https://journals.sagepub.com/doi/full/10.1177/0333102420905132?url_ver=Z39.88- 2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed 2. Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 2020;94:e1365-e1377. https://n.neurology.org/content/94/13/e1365.long DEVELOPED BY
